In the accompanying article, Jani et al 2 provide the necessary complement to this clinical success by examining economic value. Their cost-utility analysis, grounded in ADRIATIC outcomes, addresses ...
Previously, the primary endpoint results of the NRG-LU005 study assessing the addition of the immunotherapy drug atezolizumab to standard of care concurrent chemoradiation for limited-state small cell ...
MORRISTOWN, NJ, UNITED STATES, March 17, 2026 /EINPresswire.com/ — Pharmacosmos today announced the initiation of a phase III, randomised, double-blind, placebo ...
Zai Lab Limited announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer ...
Patterns of Complementary Medicine Utilization in Patients With Breast Cancer and Colorectal Cancer: A Cross-Sectional Study at a Tertiary Referral Hospital in Yogyakarta, Indonesia A partitioned ...
Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...
Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's 2026 AACR Investor Call. [Operator Instructions] As a reminder, today's call is being recorded. It is now my pleasure ...
Lung02 phase 3 trial evaluating the efficacy and safety of ifinatamab deruxtecan versus treatment of physician’s choice of chemotherapy (amrubicin, lurbinectedin or topotecan) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results